Abstract
We have evaluated the toxicity of the antitumor agent spirogermanium on a schedule of continuous intravenous administration for periods up to five days. The doses tested were between 100 mg/m2/day and 500 mg/m2/day. Peripheral vein phlebitis occurred at all dose levels and was not relieved by addition of hydrocortisone or heparin to the infusion. No phlebitis occurred when the drug was administered through a central vein. The dose limiting toxicity of spirogermanium was neurologic, notably tremors and mental confusion. These problems became progressively more severe at doses above 250 mg/m2/day. There was no discernible bone marrow, renal or hepatic toxicity. One patient developed reversible interstitial pneumonitis. The recommended Phase II dose of spirogermanium is 200 mg/m2/day for five days, with the possibility of escalation in selected patients. Because spirogermanium is more toxic to tumor cells with prolonged exposure than with intermittent exposure, this schedule could be considered for Phase II trials, particularly in diseases thought to be especially sensitive such as ovarian and prostatic carcinoma or lymphomas.
Similar content being viewed by others
References
Rice L, Wheeler JW, Geschickter CF: Spirans XXII: Synthesis of 4,4-dialkyl-4-germacyclohexanone and 8,8-dialkyl-8-germaazaspiro (4.5) decanes. J Heterocyclic Chem 11: 1041–1047, 1974
Woolley P, Maguire P, Fox P, Hoth D, Slavik M, Schein P: Studies with the antitumor agent spirogermanium. (Abstract). Proc Amer Soc Clin Onc 20:436, 1979
Slavik M, Blanc O, Davis J: Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity. Invest N Drugs 1:225–234, 1983
Henry MC, Rosen E, Port CD, Levine BS: Toxicity of spirogermanium in mice and dogs after IV or IM administration. Cancer Treat Rep 64:1207–1210, 1980
Schein PS, Slavik M, Smythe T, Hoth DF, Smith FP, Macdonald JS, Woolley PV: Phase I clinical trial of spirogermanium. Cancer Treat Rep 64:1051–1056, 1980
Mattsson W: A Phase I study of spirogermanium. (Abstract) Proc Amer Assoc Cancer Res 21:194, 1980
Budman DR, Schulman P, Vinciguerra V, Degnan TJ: Phase I Trial of spirogermanium given by infusion in a multiple dose schedule. Cancer Treat Rep 66:173–175, 1982
Legha SS, Ajani J, Bodey, GP: Phase I evaluation of spirogermanium administered on three daily schedules. J Clin Onc 1:331–336, 1983
Espana P, Kaplan R, Smith F, Robichaud K, Gustafson P, Wiernik P, Schein P: A Phase II clinical trial of spirogermanium in lymphoma patients. (Abstract). Proc Am Soc Clin Onc 1:115, 1982
Trope C, Mattson W, Gynning I, Johnson JE, Sigurdsson K, Orbert B: Phase II study of spirogermanium in advanced ovarian malignancy. Cancer Treat Rep: 119–120, 1981
Hill BT, Whatley SA, Bellamy AS, Jenkins LY, Whelan RDH: Cytotoxic effects and biological activities of 2-aza-8-germanospiro (4.5)-decane-2-propanamine-8,8-diethyl-N,N-dimethyldichloride (NSC-192965 spirogermanium) in vitro. Cancer Res 42:2852–2856, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Woolley, P.V., Ahlgren, J.D., Byrne, P.J. et al. A Phase I trial of spirogermanium administered on a continuous infusion schedule. Invest New Drugs 2, 305–309 (1984). https://doi.org/10.1007/BF00175381
Issue Date:
DOI: https://doi.org/10.1007/BF00175381